Investigating how microglial signaling affects inflammation and degeneration in Alzheimer's disease
Official title: Unraveling microglial NOD2/RIPK2 signaling: Implications for neuroinflammation and neurodegeneration in Alzheimer's disease
Funded at Johns Hopkins University · NIH-11102395 · Data updated 2026-11-12
This study is looking at how certain signals in the brain might affect inflammation and cell damage in Alzheimer's disease, with the hope of finding new ways to help reduce these harmful effects for people living with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | May 15, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $622,086 |
| NIH project number | 1R01AG092547-01 |
| Project ID | NIH-11102395 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting early signs of cognitive decline related to neurodegeneration.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on understanding the role of specific signaling pathways in the brain, particularly how the NOD2/RIPK2 pathway influences inflammation and cell damage in Alzheimer's disease. By studying the interaction between amyloid-beta aggregates and microglial cells, the researchers aim to uncover the mechanisms that lead to neuroinflammation and neurodegeneration. The study employs advanced techniques to analyze protein interactions and assess the effects of manipulating these pathways in mouse models of Alzheimer's. The ultimate goal is to identify potential new treatments that could mitigate the harmful effects of neuroinflammation in patients with Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that reduce neuroinflammation and slow the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in targeting neuroinflammatory pathways in Alzheimer's, indicating that this approach could be a viable avenue for treatment.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Ko, Hanseok — Johns Hopkins University
- Study coordinator: Ko, Hanseok
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.